Review of the Omnipod® 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes

Ther Deliv. 2020 Aug;11(8):507-519. doi: 10.4155/tde-2020-0055. Epub 2020 Jul 28.

Abstract

Type 1 diabetes (T1D) is a medical condition that requires constant management, including monitoring of blood glucose levels and administration of insulin. Advancements in diabetes technology have offered methods to reduce the burden on people with T1D. Several hybrid closed-loop systems are commercially available or in clinical trials, each with unique features to improve care for patients with T1D. This article reviews the Omnipod® 5 Automated Glucose Control System Powered by Horizon™ and the safety and efficacy data to support its use in the management of T1D.

Keywords: AP; CGM; HCL; Omnipod® 5 System; T1D; artificial pancreas; automated insulin delivery; insulin pump.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Blood Glucose Self-Monitoring
  • Blood Glucose*
  • Diabetes Mellitus, Type 1* / drug therapy
  • Glucose
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Insulin Infusion Systems

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Glucose